Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
13.04.2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
13.04.2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
Finazzi T, Rordorf T, Ikenberg K, Huber G, Guckenberger M, Garcia Schueler H. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. BMC cancer 2018; 18:395.
06.04.2018Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
06.04.2018BMC cancer 2018; 18:395
Finazzi T, Rordorf Tamara, Ikenberg K, Huber Gerhard, Guckenberger M, Garcia Schueler H I
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Loibl S, Kronenwett R, von Minckwitz G, Staebler A, Müller V, Darb-Esfahani S, Hartmann A, Furlanetto J, Kümmel S, Pfitzner B, Engels K, Schem C, Marme F, Krappmann K, Huober J, Weber K, Denkert C. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res 2018; 24:3358-3365.
04.04.2018Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
04.04.2018Clin Cancer Res 2018; 24:3358-3365
Loibl Sibylle, Kronenwett Ralf, von Minckwitz Gunter, Staebler Annette, Müller Volkmar, Darb-Esfahani Silvia, Hartmann Arndt, Furlanetto Jenny, Kümmel Sherko, Pfitzner Berit Maria, Engels Knut, Schem Christian, Marme Frederik, Krappmann Kristin, Huober Jens, Weber Karsten, Denkert Carsten
[A Rare Cause for Transient Aphasia after Conorary Angiography]
Schilling C, Weilenmann D, Diener S, Hundsberger T. [A Rare Cause for Transient Aphasia after Conorary Angiography]. Praxis (Bern 1994) 2018; 107:531-534.
03.04.2018[A Rare Cause for Transient Aphasia after Conorary Angiography]
03.04.2018Praxis (Bern 1994) 2018; 107:531-534
Schilling Carin, Weilenmann Daniel, Diener Suzie, Hundsberger Thomas
The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.
15.03.2018The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
15.03.2018JOR Spine 2018; 1:e1003
Krupkova Olga, Cambria Elena, Besse Lenka, Besse Andrej, Bowles Robert, Wuertz-Kozak Karin
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
15.03.2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
15.03.2018J Clin Oncol 2018; 36:1308-1316
Untch Michael, Loibl Sibylle, Nekljudova Valentina, Fehm Tanja, Hauschild Maik, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Huober Jens, Hanusch Claus, Eggemann Holm, Tesch Hans, Fasching Peter A, Rezai Mahdi, Schem Christian, Gerber Bernd, von Minckwitz Gunter, GBG and the AGO-B Study Group
Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies
Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt C, ess s. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open 2018; 8:e017806.
14.03.2018Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies
14.03.2018BMJ Open 2018; 8:e017806
Herrmann Christian, Vounatsou Penelope, Thürlimann Beat, Probst-Hensch Nicole, Rothermundt Christian, ess silvia
Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n
Lüscher D, Diethelm M, Hundsberger T, Hitz F. Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n. Praxis (Bern 1994) 2018; 107:329-333.
14.03.2018Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n
14.03.2018Praxis (Bern 1994) 2018; 107:329-333
Lüscher Daniel, Diethelm Markus, Hundsberger Thomas, Hitz Felicitas
Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
Fehr M, Maranta A, Reichegger H, Gillessen Sommer S, Cathomas R. Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. ESMO Open 2018; 3:e000320.
08.03.2018Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
08.03.2018ESMO Open 2018; 3:e000320
Fehr Martin, Maranta Angela Fischer, Reichegger Hermann, Gillessen Sommer Silke, Cathomas Richard
EML4-ALK Variant Affects ALK Resistance Mutations
Früh M, Peters S. EML4-ALK Variant Affects ALK Resistance Mutations. J Clin Oncol 2018; 36:1257-1259.
01.03.2018EML4-ALK Variant Affects ALK Resistance Mutations
01.03.2018J Clin Oncol 2018; 36:1257-1259
Früh Martin, Peters Solange
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. Swiss Med Wkly 2018; 148:w14589.
01.03.2018Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
01.03.2018Swiss Med Wkly 2018; 148:w14589
Passweg Jakob R, Masouridi-Levrat Stavroula, Müller Antonia, Nair Gayathri, Pabst Thomas, Renner Christoph, Schmidt Adrian, Stussi Georg, Nicoloso de Faveri Grazia, Schanz Urs, Leibundgut Kurt, Hess Urs, Heim Dominik, Baldomero Helen, Ansari Marc, Baerlocher Gabriela M, Bargetzi Mario, Chalandon Yves, Duchosal Michel A, Gerull Sabine, Güngör Tayfun, Halter Jörg P, For The Swiss Blood Stem Cell Transplantation Group Sbst
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19:497-509.
28.02.2018Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
28.02.2018Lancet Oncol 2018; 19:497-509
Loibl Sibylle, Liu Xuan, Symmans W Fraser, Rastogi Priya, Metzger Filho Otto, Ponce Lorenzo Jose J, McIntyre Kristi, Wolmark Norman, Sullivan Danielle, Maag David, von Minckwitz Gunter, Golshan Mehra, Huober Jens, McKee Mark D, Rugo Hope S, Sikov William M, Untch Michael, O'Shaughnessy Joyce, Geyer Charles E
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Neven P, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé V, Van Calster B, Jörger M, Verhoeven D, Berteloot P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné A, Brouckaert O, Decloedt J, Guchelaar H. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res 2018; 24:2312-2318.
19.02.2018Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
19.02.2018Clin Cancer Res 2018; 24:2312-2318
Neven Patrick, Vuylsteke Peter, Wynendaele Wim, Casteels Minne, Van Huffel Sabine, Lybaert Willem, Van Ginderachter Johan, Paridaens Robert, Vergote Ignace, Dezentjé Vincent Olaf, Van Calster Ben, Jörger Markus, Verhoeven Didier, Berteloot Patrick, Jongen Lynn, Lintermans Anneleen, Van Asten Kathleen, Blomme Chantal, Lambrechts Diether, Poppe An, Wildiers Hans, Dieudonné Anne-Sophie, Brouckaert Olivier, Decloedt Jan, Guchelaar Henk-Jan
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 2018; 36:1073-1079.
14.02.2018Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
14.02.2018J Clin Oncol 2018; 36:1073-1079
Wapnir Irene L, Gelber Shari, Coates Alan S, Gelber Richard D, Rastogi Priya, Regan Meredith M, Wolmark Norman, Aebi Stefan, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer Charles E, Mamounas Eleftherios P, Thürlimann Beat, Price Karen N, Anderson Stewart J, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, Láng István, Baena-Cañada José Manuel, Breast International Group
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland
Sandmeier N, Vogt D, Beyer J, Müller B, von Burg P, Berthold D, Schardt J, Cathomas R, Rothermundt C, Rothschild S, Stenner F. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. Clin Genitourin Cancer 2018
02.02.2018Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland
02.02.2018Clin Genitourin Cancer 2018
Sandmeier Nadja, Vogt Deborah R, Beyer Jörg, Müller Beat, von Burg Philippe, Berthold Dominik, Schardt Julian, Cathomas Richard, Rothermundt Christian, Rothschild Sacha I, Stenner Frank
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
Klopp-Schulze L, Jörger M, Wicha S, Ter Heine R, Csajka C, Parra-Guillen Z, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet 2018; 57:229-242.
01.02.2018Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
01.02.2018Clin Pharmacokinet 2018; 57:229-242
Klopp-Schulze Lena, Jörger Markus, Wicha Sebastian G, Ter Heine Rob, Csajka Chantal, Parra-Guillen Zinnia P, Kloft Charlotte
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger A. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep 2018; 18:3.
01.02.2018Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
01.02.2018Curr Neurol Neurosci Rep 2018; 18:3
Astaras Christophoros, de Micheli Rita, Moura Bianca, Hundsberger Thomas, Hottinger Andreas F
When and how to use carboplatin in metastatic castration-resistant prostate cancer?
Omlin A, Gillessen Sommer S. When and how to use carboplatin in metastatic castration-resistant prostate cancer?. Eur J Cancer 2018; 92:96-99.
31.01.2018When and how to use carboplatin in metastatic castration-resistant prostate cancer?
31.01.2018Eur J Cancer 2018; 92:96-99
Omlin Aurelius, Gillessen Sommer Silke
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
31.01.2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
31.01.2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
Vitamin D levels in Swiss breast cancer survivors
Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.
29.01.2018Vitamin D levels in Swiss breast cancer survivors
29.01.2018Swiss Med Wkly 2018; 148:w14576
Baumann Michael, Templeton Arnoud J, Ruhstaller Thomas, Riesen Walter F, Mark Michael Thomas, Klingbiel Dirk, Hochstrasser Andreas, Dietrich Daniel, Dani Sergio Ulhoa, Thürlimann Beat